Brief: Junshi Biosciences Announces Approval Of The sNDA For Toripalimab For The 1st-Line Treatment Of Advanced TNBC
25/06/2024 13:36
June 25 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* JUNSHI BIOSCIENCES ANNOUNCES APPROVAL OF THE SNDA FOR
TORIPALIMAB FOR THE 1ST-LINE TREATMENT OF ADVANCED TNBC
Source text for Eikon: ID:nGNX5cWpPt
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab